Drug-Eluting Stents Beat Bare-Metal Stents in Acute MI Analysis

In a large observational study, 2-year survival and repeat revascularization rates were better in DES recipients than in BMS recipients.

In randomized trials, drug-eluting stents (DES) in acute MI have been associated with reduced rates of target-vessel revascularization (TVR) compared with bare-metal stents (BMS). These trials, however, have been underpowered for mortality analysis. Using a state-mandated registry of percutaneous coronary interventions, researchers examined outcomes in 7217 patients with acute MI who underwent PCI and stent implantation at 21 Massachusetts hospitals during an 18-month period. About half the patients had ST-segment-elevation MI. DES (71% of which were sirolimus-eluting) were used in 56% of patients, and BMS were used in the remainder.

After propensity score matching to adjust for baseline differences between DES and BMS recipients, mortality …

Reviewing Author

Howard C. Herrmann, MD

Disclosures

Consultant/Advisory BoardAffluent Medical; Artedrone; Caranx; Johnson & Johnson; Medtronic; Prolifagen; Wells Fargo

EquityMicrointerventional Devices, Inc.

RoyaltiesUniversity of Pennsylvania

Grant/Research SupportAbbott Vascular; Edwards Lifesciences; Johnson & Johnson; Medtronic

Editorial BoardsCatheterization and Cardiovascular Interventions; Journal of the American College of Cardiology; Circulation: Cardiovascular Interventions; JACC Cardiovascular Interventions; JACC Case Reports; JSCAI